Truist Financial
ONCY

Truist Financial’s Oncolytics Biotech ONCY Stock Holding History

Truist Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Hold
20,000
– – ﹤0.01% 2904
2026
Q1 		$17K Buy
+20,000
New +$19.9K ﹤0.01% 2779

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Truist Financial's ONCY Position: Q2 2026 in Review

Truist Financial held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 20,000 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Truist Financial first reported a position in ONCY in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Truist Financial held 20,000 shares of Oncolytics Biotech worth $19K as of Q2 2026.
  • Truist Financial left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2904 holding.
  • Truist Financial first reported a position in Oncolytics Biotech in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.